Pharvaris NV

PHVS · NASDAQ

$31.41+$0.73 (+2.38%)TodayMarket closed · Oct 23, 7:30 PM ET

Prev close $30.68

Latest news

NewsOct 23, 2:06 PM ETVandana Singh
Two Pills, One Target: Analyst Bets on Pharvaris as Clinical Risks Fade
NewsOct 9, 3:05 AM ET
Reported Earlier, Pharvaris Says Lancet-Published Phase 3 Data Show Deucrictibant IR Delivered Symptom Relief In 1.28 Hours And Complete Resolution In 11.95 Hours For HAE Attacks, With NDA And MAA Under Review
Press releaseOct 8, 6:35 PM ETGlobe Newswire
Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet
Press releaseOct 5, 6:50 AM ETGlobe Newswire
Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy
NewsSep 8, 12:02 PM ETAvi Kapoor
Crude Oil Gains 1.5%; ABM Posts Upbeat Q3 Earnings
NewsSep 8, 9:59 AM ETVandana Singh
Why Is Pharvaris Stock Soaring Tuesday?
Press releaseSep 8, 6:50 AM ETGlobe Newswire
Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks
Press releaseSep 3, 6:50 AM ETGlobe Newswire
Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026
Press releaseAug 12, 6:50 AM ETGlobe Newswire
Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update
Press releaseAug 6, 6:50 AM ETGlobe Newswire
Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology
Press releaseJul 22, 6:50 AM ETGlobe Newswire
Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema
Press releaseJul 6, 6:50 AM ETGlobe Newswire
Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks
Press releaseJun 15, 6:50 AM ETGlobe Newswire
Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026
Press releaseMay 29, 6:50 AM ETGlobe Newswire
Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026
Press releaseMay 12, 4:05 PM ETGlobe Newswire
Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update
NewsApr 2, 7:11 AM ET
Earnings Scheduled For April 2, 2026
Press releaseFeb 10, 6:50 AM ETGlobe Newswire
Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting
Press releaseJan 12, 6:50 AM ETGlobe Newswire
Pharvaris Outlines 2026 Strategic Priorities
NewsDec 3, 10:09 AM ETVandana Singh
Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows
Press releaseNov 12, 6:50 AM ETGlobe Newswire
Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update
Press releaseNov 10, 6:50 AM ETGlobe Newswire
Data Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific Meeting
Press releaseOct 23, 6:50 AM ETGlobe Newswire
Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting
Press releaseAug 12, 4:05 PM ETGlobe Newswire
Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update
Press releaseJun 27, 6:50 AM ETGlobe Newswire
Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit
Press releaseJun 16, 6:50 AM ETGlobe Newswire
Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress
Press releaseJun 2, 6:50 AM ETGlobe Newswire
Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema
Press releaseMay 19, 6:50 AM ETGlobe Newswire
Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses
Press releaseMay 13, 4:05 PM ETGlobe Newswire
Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update
Press releaseMay 12, 6:50 AM ETGlobe Newswire
Pharvaris to Host a Virtual R&D Call "Deucrictibant: Beyond HAE Type 1/2" on June 4
Press releaseApr 7, 6:58 AM ETGlobe Newswire
Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Press releaseMar 3, 6:50 AM ETGlobe Newswire
Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress
Press releaseMar 3, 6:48 AM ETGlobe Newswire
Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025
Press releaseJan 13, 6:50 AM ETGlobe Newswire
Pharvaris Outlines 2025 Strategic Priorities
Press releaseNov 13, 4:10 PM ETGlobe Newswire
Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
Press releaseNov 12, 6:50 AM ETGlobe Newswire
Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference
Press releaseOct 30, 6:00 AM ETPRNewswire
Axonis Therapeutics Announces $115 Million Series A Financing
Press releaseOct 24, 8:00 AM ETGlobe Newswire
Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Two Pills, One Target: Analyst Bets on Pharvaris as Clinical Risks Fade

Reported Earlier, Pharvaris Says Lancet-Published Phase 3 Data Show Deucrictibant IR Delivered Symptom Relief In 1.28 Hours And Complete Resolution In 11.95 Hours For HAE Attacks, With NDA And MAA Under Review

Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet

Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy

Crude Oil Gains 1.5%; ABM Posts Upbeat Q3 Earnings

Why Is Pharvaris Stock Soaring Tuesday?

Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks

Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026

Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update

Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology

Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema

Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks

Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026

Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026

Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update

Earnings Scheduled For April 2, 2026

Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting

Pharvaris Outlines 2026 Strategic Priorities

Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows

Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update

Data Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific Meeting

Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting

Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update

Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit

Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress

Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema

Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses

Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update

Pharvaris to Host a Virtual R&D Call "Deucrictibant: Beyond HAE Type 1/2" on June 4

Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress

Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025

Pharvaris Outlines 2025 Strategic Priorities

Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference

Axonis Therapeutics Announces $115 Million Series A Financing

Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting